Insulin resistance improving agent

a technology of improving agent and insulin, which is applied in the direction of peptide/protein ingredients, extracellular fluid disorder, metabolic disorder, etc., can solve the problem that adiponectin is not effective in the actual treatment of diabetes, and the effect of reducing expression or loss of expression

Inactive Publication Date: 2006-09-07
JAPAN SCI & TECH CORP
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The present inventors have investigated effects of adiponectin through use of model mice of different types; i.e., mice in which insulin sensitivity had been modified, obese mice, and type 2 diabetes mice, and have found that decrease in expression or loss of expression of adiponectin is a cause for development of insulin resistance, and that administration of adiponectin or a fragment of adiponectin, or introduction of any of their genes, is effective for the treatment of insulin-resistant diabetes and type 2 diabetes, thereby leading to completion of the invention.

Problems solved by technology

However, whether or not adiponectin is effective in the actual treatment of diabetes remains unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Insulin resistance improving agent
  • Insulin resistance improving agent
  • Insulin resistance improving agent

Examples

Experimental program
Comparison scheme
Effect test

examples

[0032] The present invention will next be described in more detail by way of Examples, which should not be construed as limiting the invention thereto.

A. Methods

(1) Chemicals

[0033] Rosiglitazone (PPAR-γ agonist) and HX531 (PPAR-γ / RXR inhibitor) were synthesized as described in the literature (Chem. Pharm. Bull. (Tokyo) 47, 1778-1786 (1999), Diabetes 47, 1841-1847 (1998)).

(2) Animals

[0034] PPAR-γ+ / − mice were prepared in a manner which had already been reported (Mol. Cell 4, 597-609 (1999)). All other animals were purchased from Nippon CREA. Six-week-old mice were fed powdered chow, and drugs were given as feed admixtures as described (Mol. Cell 4, 597-609 (1999)).

(3) RNA Preparation, Northern-Blot Analysis, and Immunoblotting

[0035] Total RNA was prepared from tissues through use of TRIzol (GIBCO-BRL) according to the manufacturer's instructions. RNA obtained from 5 to 10 mice in each group was pooled, and aliquots were subjected to northern blot analysis with the probes f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
resistanceaaaaaaaaaa
excess energyaaaaaaaaaa
Login to view more

Abstract

The invention provides an insulin resistance improving agent which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a therapeutic agent for type 2 diabetes, which contains, as an active component, a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention reverses insulin resistance induced from a high fat diet and associated with obesity, and therefore, enables treatment of type 2 diabetes, which is the most common among other types of diabetes.

Description

TECHNICAL FIELD [0001] The present invention relates to an insulin resistance improving agent useful for the prevention and treatment of obesity, diabetes, and cardiovascular diseases, as well as to a drug for treating type 2 diabetes. BACKGROUND ART [0002] Hitherto, adipose tissue has been considered a mere storage medium for excess energy. However, recent research has elucidated that adipose tissue produces and secretes a variety of physiologically active substances. The physiologically active substances are collectively called adipocytokines, and specific members which have been known to date include leptin, tumor necrosis factor-α (TNF-α), plasminogen-activator inhibitor type 1 (PAI-1), adipsin, and resistin. Some of these adipocytokines, such as leptin, TNF-α, and resistin, have been suggested to be secreted from adipocytes to thereby control sensitivity to insulin. [0003] Adiponectin has recently been identified as an adipocytokine. Adiponectin was originally identified indepe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17A61K48/00A61K38/22A61P3/04A61P3/10A61P43/00
CPCA61K38/2264A61P3/00A61P3/04A61P3/10A61P9/00A61P43/00
Inventor KADOWAKI, TAKASHIYAMAUCHI, TOSHIMASAKAMON, JUNJIWAKI, HIRONORINAGAI, RYOZOKIMURA, SATOSHITOMITA, MOTTO
Owner JAPAN SCI & TECH CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap